Base de dados : MEDLINE
Pesquisa : D04.210.500.745.432.719.320 [Categoria DeCS]
Referências encontradas : 262 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 27 ir para página                         

  1 / 262 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:25007376
[Au] Autor:Del Rosso JQ; Kircik LH
[Ti] Título:Transitioning from brand to generic with topical products and the importance of maintaining the formulation and therapeutic profiles of the original product: focus on clocortolone pivalate 0.1% cream.
[So] Source:J Drugs Dermatol;13(7):s77-83, 2014 Jul.
[Is] ISSN:1545-9616
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Topical corticosteroids (TCSs) are a major part of the foundation of treatment for a wide variety of eczematous and inflammatory skin disorders in both adults and children. Mid-potency TCSs represent an important category as they are often used to treat eczematous dermatoses, such as atopic dermatitis. The TCS product must effectively release the active ingredient and promote cutaneous penetration so that therapeutic activity can occur. As many topical products eventually become available as generic formulations, it is important to recognize that although the active ingredient and its concentration are the same, the vehicle excipients may differ significantly, occasionally leading to potential differences in irritancy, in allergenicity, in effects on epidermal permeability barrier function, and, possibly, in efficacy. Clocortolone pivalate 0.1% cream is a mid-potency TCS formulated in an emollient formulation that has been shown to be effective and well-tolerated in the management of several corticosteroid-responsive dermatoses. This article outlines the pharmacologic and clinical data achieved with the original brand formulation of clocortolone pivalate 0.1% cream, and discusses the establishment of an authorized generic formulation that is identical in formulation to the original brand.
[Mh] Termos MeSH primário: Medicamentos Genéricos/administração & dosagem
Fluocortolona/análogos & derivados
Glucocorticoides/administração & dosagem
[Mh] Termos MeSH secundário: Administração Cutânea
Adulto
Criança
Fármacos Dermatológicos/administração & dosagem
Fármacos Dermatológicos/efeitos adversos
Fármacos Dermatológicos/uso terapêutico
Medicamentos Genéricos/efeitos adversos
Medicamentos Genéricos/uso terapêutico
Eczema/tratamento farmacológico
Eczema/patologia
Excipientes/química
Fluocortolona/administração & dosagem
Fluocortolona/efeitos adversos
Fluocortolona/uso terapêutico
Glucocorticoides/efeitos adversos
Glucocorticoides/uso terapêutico
Seres Humanos
Inflamação/tratamento farmacológico
Inflamação/patologia
Dermatopatias/tratamento farmacológico
Dermatopatias/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Dermatologic Agents); 0 (Drugs, Generic); 0 (Excipients); 0 (Glucocorticoids); 65VXC1MH0J (Fluocortolone); QBL8IZH14X (clocortolone pivalate)
[Em] Mês de entrada:1503
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140710
[St] Status:MEDLINE


  2 / 262 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:24809882
[Au] Autor:Kircik LH
[Ti] Título:A study to assess the occlusivity and moisturization potential of three topical corticosteroid products using the skin trauma after razor shaving (STARS) bioassay.
[So] Source:J Drugs Dermatol;13(5):582-5, 2014 May.
[Is] ISSN:1545-9616
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Dysfunction of the epidermal barrier is generally considered a precursor of cutaneous inflammation that can directly contribute to the pathogenesis of skin diseases, notably atopic dermatitis (AD). We also know that topical corticosteroids may actually impair the epidermal barrier by interfering with epidermal lipid synthesis. Therefore, it is important to utilize topical corticosteroids in vehicles that will help at least to enhance the already disrupted epidermal barrier in atopic dermatitis patients. Two studies of identical design were conducted to determine and compare the occlusivity and moisturizing potential of three topical corticosteroid products when applied to skin whose barrier integrity has been disrupted by dry shaving. Findings in both studies showed the clocortolone pivalate cream decreased TEWL better than non-treatment or treatment with hydrocortisone butyrate lotion. Skin surface hydration increased significantly (P<0.001) in all three treated sites, compared to the non-treated damaged control and non-treated normal skin. Clocortolone pivalate cream increased skin surface hydration significantly (P<0.001) better than hydrocortisone butyrate lipocream or hydrocortisone butyrate lotion. These studies showed that clocortolone pivalate cream enhances barrier function by providing occlusion. While understanding of the structure and function of the stratum corneum (SC) and epidermal barrier function has evolved tremendously over the last several decades, and especially over the last 15 years,1 confusion and misinformation still persist. Dysfunction of the epidermal barrier is generally considered a precursor of cutaneous inflammation that can directly contribute to the pathogenesis of skin diseases, notably atopic dermatitis (AD).2,3 Topical steroids are standard of care in treatment of atopic dermatitis. However, we also know that topical corticosteroids may actually impair epidermal barrier by interfering with epidermal lipid synthesis.4,5 In addition to that, various penetration enhancers in the topical steroid formulations also contribute to the impairment of the epidermal barrier.4 Therefore, it is important to utilize topical corticosteroids in vehicles that will help at least to enhance the already disrupted epidermal barrier in atopic dermatitis patients. In this regard, these studies were designed to determine the hydrating effects of clocortolone pivalate cream 0.1% (Cloderm Cream, Promius Pharma).
[Mh] Termos MeSH primário: Fármacos Dermatológicos/farmacologia
Fluocortolona/análogos & derivados
Glucocorticoides/farmacologia
Hidrocortisona/análogos & derivados
[Mh] Termos MeSH secundário: Administração Cutânea
Adulto
Bioensaio
Dermatite Atópica/tratamento farmacológico
Dermatite Atópica/patologia
Fármacos Dermatológicos/administração & dosagem
Emolientes/administração & dosagem
Emolientes/farmacologia
Epiderme/efeitos dos fármacos
Epiderme/patologia
Fluocortolona/administração & dosagem
Fluocortolona/farmacologia
Glucocorticoides/administração & dosagem
Seres Humanos
Hidrocortisona/administração & dosagem
Hidrocortisona/farmacologia
Meia-Idade
Pele/efeitos dos fármacos
Pele/patologia
Dermatopatias/tratamento farmacológico
Dermatopatias/patologia
Resultado do Tratamento
Perda Insensível de Água/efeitos dos fármacos
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Dermatologic Agents); 0 (Emollients); 0 (Glucocorticoids); 05RMF7YPWN (hydrocortisone-17-butyrate); 65VXC1MH0J (Fluocortolone); QBL8IZH14X (clocortolone pivalate); WI4X0X7BPJ (Hydrocortisone)
[Em] Mês de entrada:1412
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140510
[St] Status:MEDLINE


  3 / 262 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24225379
[Au] Autor:Prokosch V; Thanos S
[Ad] Endereço:Institute of Experimental Ophthalmology, Westfälische Wilhelms-Universität Münster, Münster, Germany.
[Ti] Título:Visual outcome of patients following NAION after treatment with adjunctive fluocortolone.
[So] Source:Restor Neurol Neurosci;32(3):381-9, 2014.
[Is] ISSN:1878-3627
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Nonarteriitic anterior ischemic optic neuropathy (NAION) is a leading cause of sudden loss of vision, which particularly affects individuals older than 50 years. Up to now there is no treatment that is effective at reversing or limiting the course of this disease. To study the short- and long-term effects of fluocortolone (FC) on the visual outcome of patients with acute NAION compared to standard treatment with pentoxifylline (PFX). METHODS: A prospective, quasirandomized intervention trial was conducted involving 60 patients with acute-onset NAION. Patients in the comparison (PFX) group (n = 30) received PFX intravenously and per os for 7 days and then per os for a further 6 months, which is a standard treatment. Patients in the intervention (PFX + FC) group (n = 30) received the standard treatment plus 1 mg/kg FC for 5 days, with a subsequent stepwise dose reduction over time. As a primary outcome measure, the best corrected visual acuity (BCVA) was determined at the initial baseline consultation (i.e., before treatment), and at 3 days and 6 months after therapy onset. Visual field (VF) was analyzed using standard automated perimetry at the initial baseline examination and at 6 month after therapy onset. Changes in BCVA and visual field in the PFX and PFX + FC groups were compared and analyzed statistically. RESULTS: Treatment with FC resulted in a significant improvement in BCVA. Patients receiving FC in acute NAION were more likely to experience improvement and less likely to have worsened visual acuity (mean BCVA scores: at baseline, 0.22; after 3 days and 6 months of treatment, 0.33 and 0.43, respectively) than PFX patients (mean BCVA scores: at baseline, 0.33; after 3 days and 6 months of treatment, 0.33 and 0.28, respectively; p < 0.002 and 0.001). The beneficial effect was even more marked 6 months after therapy onset. Remarkably, patients with a baseline BCVA score of >=0.05 profited significantly by FC treatment (p < 0.006 and 0.001), whereas those with a baseline BCVA score of <0.05 did not (p < 0.4). PFX did not improve BCVA. However, VF did not show any significant improvement due to FC therapy. CONCLUSION: This is the first prospective randomized intervention trial that demonstrates the distinctive beneficial effects of FC in terms of the visual outcome of patients with NAION compared to standard treatment with only PFX. FC significantly improves both short- and long-term visual acuity in patients with moderate BCVA impairment due to recent onset of NAION, while VF did not show any significant improvement; however, PFX did neither enhance BCVA nor VF. Administration of FC should be seriously considered for the treatment of NAION whenever there are no contraindications.
[Mh] Termos MeSH primário: Fluocortolona/uso terapêutico
Fármacos Neuroprotetores/uso terapêutico
Neuropatia Óptica Isquêmica/tratamento farmacológico
Pentoxifilina/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Feminino
Seres Humanos
Masculino
Meia-Idade
Estudos Prospectivos
Fatores de Tempo
Resultado do Tratamento
Testes Visuais
Acuidade Visual/efeitos dos fármacos
[Pt] Tipo de publicação:CLINICAL TRIAL; COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Neuroprotective Agents); 65VXC1MH0J (Fluocortolone); SD6QCT3TSU (Pentoxifylline)
[Em] Mês de entrada:1501
[Cu] Atualização por classe:140603
[Lr] Data última revisão:
140603
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:131115
[St] Status:MEDLINE
[do] DOI:10.3233/RNN-120292


  4 / 262 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:23377405
[Au] Autor:Del Rosso JQ; Kircik LH
[Ad] Endereço:Valley Hospital Medical Center, Las Vegas, NV, USA.
[Ti] Título:The role of a midpotency topical corticosteroid and the clinical relevance of formulation characteristics in the management of commonly encountered eczematous and inflammatory dermatoses in adults and children: focus on the pharmacologic properties of clocortolone pivalate 0.1% cream.
[So] Source:J Drugs Dermatol;12(2):s5-s10, 2013 Feb.
[Is] ISSN:1545-9616
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Midpotency topical corticosteroids (TCSs) are frequently used for the treatment of common eczematous and inflammatory skin disorders in both adults and children. There are several commercially available products in this category, and many vehicles and formulations for the clinician to choose from. Clocortolone pivalate 0.1% cream is a midpotency TCS formulated in an emollient formulation that has been shown to be effective and well tolerated when used appropriately in the management of several corticosteroid-responsive dermatoses. This article discusses the physiochemical properties of the compound; the characteristics of its emollient cream formulation; the functions of individual excipients; and the efficacy, tolerability, and safety data supporting its use in adults and children, including for facial involvement.
[Mh] Termos MeSH primário: Eczema/tratamento farmacológico
Fluocortolona/análogos & derivados
Glucocorticoides/uso terapêutico
Dermatopatias/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Tópica
Adulto
Química Farmacêutica
Criança
Dermatite de Contato/tratamento farmacológico
Dermatite de Contato/patologia
Eczema/patologia
Face
Fluocortolona/administração & dosagem
Fluocortolona/efeitos adversos
Fluocortolona/uso terapêutico
Glucocorticoides/administração & dosagem
Glucocorticoides/efeitos adversos
Seres Humanos
Pomadas
Psoríase/tratamento farmacológico
Psoríase/patologia
Pele/patologia
Dermatopatias/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Glucocorticoids); 0 (Ointments); 65VXC1MH0J (Fluocortolone); QBL8IZH14X (clocortolone pivalate)
[Em] Mês de entrada:1308
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130205
[St] Status:MEDLINE


  5 / 262 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:23377404
[Au] Autor:Kircik LH
[Ad] Endereço:Mount Sinai Medical Center, New York, NY, USA. wedoderm@yahoo.com
[Ti] Título:Clocortolone pivalate: a topical corticosteroid with a unique structure.
[So] Source:J Drugs Dermatol;12(2):s3-4, 2013 Feb.
[Is] ISSN:1545-9616
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:As the accumulated clinical evidence and experience to be presented in the next several pages demonstrate, the unique engineering of the clocortolone pivalate molecule balances potency with documented efficacy and a favorable safety profile. Clocortolone pivalate 0.1% cream is a well-formulated and versatile therapeutic option to consider for many of our patients with steroid-responsive dermatoses.
[Mh] Termos MeSH primário: Fluocortolona/análogos & derivados
Glucocorticoides/química
Glucocorticoides/uso terapêutico
[Mh] Termos MeSH secundário: Administração Tópica
Ensaios Clínicos Fase III como Assunto
Dermatite/tratamento farmacológico
Emolientes
Fluocortolona/química
Fluocortolona/uso terapêutico
Halogênios/química
Seres Humanos
Psoríase/tratamento farmacológico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Emollients); 0 (Glucocorticoids); 0 (Halogens); 65VXC1MH0J (Fluocortolone); QBL8IZH14X (clocortolone pivalate)
[Em] Mês de entrada:1308
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130205
[St] Status:MEDLINE


  6 / 262 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:22573413
[Au] Autor:Birnbaum F; Wiggermann A; Maier PC; Böhringer D; Reinhard T
[Ad] Endereço:Eye Hospital, Klinikum Bremen-Mitte gGmbH, St.-Jürgenstr. 1, 28177 Bremen, Germany. florian.birnbaum@klinikum-bremen-mitte.de
[Ti] Título:Clinical results of 123 femtosecond laser-assisted penetrating keratoplasties.
[So] Source:Graefes Arch Clin Exp Ophthalmol;251(1):95-103, 2013 Jan.
[Is] ISSN:1435-702X
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Postoperative astigmatism following penetrating keratoplasty is a major problem after corneal transplantation. The main goal of new trephination techniques such as femtosecond laser or excimer-laser trephination is to improve refractive and visual outcomes. The femtosecond laser technique makes profiled corneal trephinations such as the top hat or mushroom profile possible. We present the postoperative outcome of femtosecond laser-assisted penetrating keratoplasties. METHODS: We performed 123 femtosecond laser-assisted penetrating keratoplasties in 119 patients. The main outcome measures were intraoperative specifics, astigmatism, and irregularity in Orbscan corneal topography, as well as the occurrence of immune reactions and side-effects. RESULTS: All sutures have been removed in 49 of these 123 eyes. Their mean follow-up was 13.9 ± 4.5 months. Time to complete suture removal (n = 49) was 12.0 ± 3.7 months in the mushroom group and 9.8 ± 2.1 months in the top hat group. Mean astigmatism in Orbscan topography was 6.4 ± 3.0 diopters in the mushroom and 5.8 ± 4.6 diopters in the top hat group (all sutures out). CONCLUSIONS: Femtosecond laser-assisted penetrating keratoplasty is a safe surgical technique. Due to the steps in profiled trephinations, the wound area is larger and theoretically the wound healing is, thus, faster and more stable. Complete suture removal is possible at an earlier time point compared to conventional penetrating keratoplasty. However, refractive results are not superior to those following conventional trephination.
[Mh] Termos MeSH primário: Astigmatismo/etiologia
Ceratoplastia Penetrante/métodos
Terapia a Laser/métodos
Complicações Pós-Operatórias
[Mh] Termos MeSH secundário: Adulto
Astigmatismo/diagnóstico
Astigmatismo/fisiopatologia
Doenças da Córnea/imunologia
Doenças da Córnea/fisiopatologia
Doenças da Córnea/cirurgia
Topografia da Córnea
Feminino
Fluocortolona/uso terapêutico
Glucocorticoides/uso terapêutico
Rejeição de Enxerto/tratamento farmacológico
Rejeição de Enxerto/imunologia
Seres Humanos
Masculino
Meia-Idade
Prednisolona/análogos & derivados
Prednisolona/uso terapêutico
Refração Ocular/fisiologia
Técnicas de Sutura
Tomografia de Coerência Óptica
Resultado do Tratamento
Acuidade Visual/fisiologia
Cicatrização/fisiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Glucocorticoids); 65VXC1MH0J (Fluocortolone); 8B2807733D (prednisolone acetate); 9PHQ9Y1OLM (Prednisolone)
[Em] Mês de entrada:1306
[Cu] Atualização por classe:170928
[Lr] Data última revisão:
170928
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120511
[St] Status:MEDLINE
[do] DOI:10.1007/s00417-012-2054-0


  7 / 262 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:23134984
[Au] Autor:Kircik LH; Del Rosso JQ
[Ad] Endereço:Indiana University School of Medicine, Indianapolis, IN, USA. wedoderm@yahoo.com
[Ti] Título:The treatment of inflammatory facial dermatoses with topical corticosteroids: focus on clocortolone pivalate 0.1% cream.
[So] Source:J Drugs Dermatol;11(10):1194-8, 2012 Oct.
[Is] ISSN:1545-9616
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Study results evaluating the efficacy and safety of clocortolone pivalate 0.1% cream in the treatment of adults, young children, and infants with inflammatory facial dermatoses are reported in this article. Clocortolone pivalate 0.1% cream, indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, is a mid-potency topical corticosteroid (Class 4) that has been studied and used extensively to treat a variety of corticosteroid-responsive inflammatory dermatoses, many of which often involve facial skin in both adults and children. METHODS: Clocortolone pivalate 0.01% cream was applied to affected facial skin in subjects presenting with seborrheic dermatitis, contact dermatitis, atopic dermatitis, or psoriasis. Application was completed three times daily for 21 days. Assessments of erythema, edema, transudation, lichenification, scaling, pruritus and/or pain were completed at baseline and Days 4, 7, 14, and 21. Overall therapeutic response was assessed at all follow-up visits. Forty-nine subjects were entered, ranging in age from 1 month to 88 years of age. Thirty-eight subjects completed the studies, with 11 subjects lost to follow-up after the first visit. Individuals between the ages of 13 and 19 years were pre-emptively excluded to avoid potential application of a corticosteroid to acne-affected or acne-prone skin. RESULTS: Treatment with clocortolone pivalate 0.1% cream resulted in decreases in erythema, edema, transudation, lichenification, scaling, and pruritus/pain in 76% of treated study subjects. The overall therapeutic response in approximately two-thirds of the subjects (68%) was rated as good to excellent. There were 7 adverse events noted over the course of the study that were judged to be related to treatment, all of which were cutaneous and localized to the site of application (acneiform eruptions, burning, and folliculitis). CONCLUSION: Clocortolone pivalate 0.1% cream was effective in relieving the signs and symptoms of corticosteroid-responsive inflammatory dermatoses involving facial skin, including seborrheic dermatitis, contact dermatitis, atopic dermatitis, and psoriasis. Overall, the safety profile was favorable and devoid of any treatment-related serious adverse events.
[Mh] Termos MeSH primário: Dermatoses Faciais/tratamento farmacológico
Fluocortolona/análogos & derivados
Glucocorticoides/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Criança
Pré-Escolar
Dermatite Atópica/complicações
Dermatite Atópica/tratamento farmacológico
Dermatite de Contato/complicações
Dermatite de Contato/tratamento farmacológico
Dermatite Seborreica/complicações
Dermatite Seborreica/tratamento farmacológico
Edema/tratamento farmacológico
Edema/etiologia
Eritema/tratamento farmacológico
Eritema/etiologia
Exsudatos e Transudatos/efeitos dos fármacos
Dermatoses Faciais/complicações
Feminino
Fluocortolona/efeitos adversos
Fluocortolona/uso terapêutico
Glucocorticoides/efeitos adversos
Seres Humanos
Lactente
Masculino
Meia-Idade
Dor/tratamento farmacológico
Dor/etiologia
Prurido/tratamento farmacológico
Prurido/etiologia
Psoríase/complicações
Psoríase/tratamento farmacológico
Creme para a Pele
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Glucocorticoids); 65VXC1MH0J (Fluocortolone); QBL8IZH14X (clocortolone pivalate)
[Em] Mês de entrada:1305
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:121109
[St] Status:MEDLINE


  8 / 262 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:22505393
[Au] Autor:Deniz K; Coban G; Ozbakir O; Deniz E
[Ti] Título:Pseudomembranous collagenous colitis.
[So] Source:Turk J Gastroenterol;23(1):93-5, 2012 Feb.
[Is] ISSN:2148-5607
[Cp] País de publicação:Turkey
[La] Idioma:eng
[Mh] Termos MeSH primário: Colite Colagenosa/diagnóstico
Enterocolite Pseudomembranosa/diagnóstico
[Mh] Termos MeSH secundário: Anti-Inflamatórios não Esteroides/uso terapêutico
Colite Colagenosa/tratamento farmacológico
Colonoscopia
Diarreia/etiologia
Enterocolite Pseudomembranosa/tratamento farmacológico
Fluocortolona/uso terapêutico
Hemorragia Gastrointestinal/etiologia
Glucocorticoides/uso terapêutico
Seres Humanos
Masculino
Mesalamina/uso terapêutico
Meia-Idade
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Glucocorticoids); 4Q81I59GXC (Mesalamine); 65VXC1MH0J (Fluocortolone)
[Em] Mês de entrada:1209
[Cu] Atualização por classe:150518
[Lr] Data última revisão:
150518
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120417
[St] Status:MEDLINE


  9 / 262 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:22264563
[Au] Autor:Xu W; Jia X; Liu W; Zhang X; Chen Y; Zhou L; You S
[Ad] Endereço:School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, People's Republic of China.
[Ti] Título:Identification and characterization of three impurities in clocortolone pivalate.
[So] Source:J Pharm Biomed Anal;62:167-71, 2012 Mar 25.
[Is] ISSN:1873-264X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Clocortolone pivalate is a synthetic corticosteroid that can be used to cure corticosteroid-responsive dermatoses. Three previously unknown impurities detected by HPLC were isolated by semi-preparative LC. Based on the NMR and MS spectral data, these were identified as (6R,9R,16R)-9-chloro-6ß-fluoro-11ß,21-dihydroxy-16α-methylpregna-1,4-diene-3,20-dione-21-pivalate (Impurity I), (9R,16R)-9-chloro-4-fluoro-11ß,21-dihydroxy-16α-methylpregna-1,4-diene-3,20-dione-21-pivalate (Impurity II) and (9R,16R)-9-chloro-6α-fluoro-11ß,21-dihydroxy-16α-methylpregna-1,4-diene-3,20-dione-11,21-dipivalate (Impurity III). The possible mechanism of the formation of the impurities is discussed.
[Mh] Termos MeSH primário: Fluocortolona/análogos & derivados
Glucocorticoides/química
[Mh] Termos MeSH secundário: Cromatografia Líquida de Alta Pressão
Fluocortolona/química
Espectroscopia de Ressonância Magnética
Espectrometria de Massas por Ionização por Electrospray
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Glucocorticoids); 65VXC1MH0J (Fluocortolone); QBL8IZH14X (clocortolone pivalate)
[Em] Mês de entrada:1206
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120124
[St] Status:MEDLINE
[do] DOI:10.1016/j.jpba.2011.11.021


  10 / 262 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:21437845
[Au] Autor:Mayer C; Khoramnia R
[Ad] Endereço:Klinik und Poliklinik für Augenheilkunde, Klinikum rechts der Isar der Technischen Universität München, München. christian.mayer@lrz.tu-muenchen.de
[Ti] Título:[Choroidal neovascularisation in a patient with punctate inner choroidopathy (PIC)].
[Ti] Título:Choroidale Neovaskularisation bei einer Patientin mit "punctate inner choroidopathy" (PIC)..
[So] Source:Klin Monbl Augenheilkd;228(10):915-7, 2011 Oct.
[Is] ISSN:1439-3999
[Cp] País de publicação:Germany
[La] Idioma:ger
[Mh] Termos MeSH primário: Doenças da Coroide/diagnóstico
Neovascularização de Coroide/diagnóstico
[Mh] Termos MeSH secundário: Adulto
Anti-Inflamatórios/administração & dosagem
Anticorpos Monoclonais Humanizados/administração & dosagem
Bevacizumab
Doenças da Coroide/tratamento farmacológico
Neovascularização de Coroide/tratamento farmacológico
Progressão da Doença
Feminino
Fluocortolona/administração & dosagem
Angiofluoresceinografia
Seguimentos
Seres Humanos
Processamento de Imagem Assistida por Computador
Oftalmoscópios
Tomografia de Coerência Óptica
Transtornos da Visão/diagnóstico
Transtornos da Visão/tratamento farmacológico
Transtornos da Visão/etiologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Antibodies, Monoclonal, Humanized); 2S9ZZM9Q9V (Bevacizumab); 65VXC1MH0J (Fluocortolone)
[Em] Mês de entrada:1204
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:110326
[St] Status:MEDLINE
[do] DOI:10.1055/s-0029-1245792



página 1 de 27 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde